EGFR and neoplasm: Following three different strategies to inhibit mutant‐specific EGFR, the tumor immune microenvironment is at least transiently converted to a more active state, providing a window of opportunity where there may be heightened sensitivity to therapies that promote immune responses against the tumor (Figure 7B).